As we dive into the market on January 26th, let’s explore three stocks that exhibit a buy rank and robust momentum traits for investors to mull over.
PACCAR Inc. – An Engine of Opportunity
PACCAR Inc. (PCAR) has been firing on all cylinders, having been graced with a Zacks Rank #1. What’s more, the Zacks Consensus Estimate for its current year earnings has surged by 5.1% over the last 60 days.
PACCAR’s shares have outperformed the S&P 500, surging 22.5% over the past three months while also boasting a Momentum Score of A.
Inhibikase Therapeutics, Inc. – A Prescription for Success
The pharmaceutical company, Inhibikase Therapeutics, Inc. (IKT), is another standout contender with a Zacks Rank #1. Its Zacks Consensus Estimate for current year earnings has flourished by 16% over the last 60 days.
Inhibikase Therapeutics’s shares have been a rocket, scaling an outstanding 195.5% over the preceding three months against the S&P 500’s advance of 18%, while also boasting a Momentum Score of A.
PagerDuty, Inc. – A Digital Torchbearer
PagerDuty, Inc. (PD) continues to shine, backed by a Zacks Rank #1 and a 16.1% surge in the Zacks Consensus Estimate for current year earnings over the last 60 days.
PagerDuty’s shares have sprinted 21.8% higher over the last three months, outpacing the S&P 500’s advance of 18%, while holding a notable Momentum Score of B.
If you hunger for more top ranked stocks, here’s the full list to feast on. And, unravel the calculus behind the Momentum score here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
PACCAR Inc. (PCAR) : Free Stock Analysis Report
PagerDuty (PD) : Free Stock Analysis Report
Inhibikase Therapeutics, Inc. (IKT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
